Q-omics provides the consensus-scored CRYBG3 profile across patient tissues and cancer cell-line models. CRYBG3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRYBG3 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CRYBG3 protein abundance shows 21,260 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where CRYBG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYBG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYBG3 survival associations across molecular data types. CRYBG3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYBG3 RNA expression–survival associations across cancer types. High CRYBG3 expression shows unfavorable associations in BLCA, LGG and THCA, but favorable associations in KIRC, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRYBG3 RNA expression.
This table summarizes CRYBG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CRYBG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYBG3 shows lower tumor expression in KIRC, THCA, UCEC, BRCA, COAD and KIRP. The KIRC box plot shows higher CRYBG3 RNA expression in normal versus tumor tissue (log2 FC = −0.855, t-test p < 0.001).
This table shows molecular features associated with CRYBG3 in patient tissues and cancer cell lines. In patient samples, CRYBG3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYBG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
